https://smallmoleculetechnologies.com/wp-content/uploads/2014/12/Small-Molecule-Technologies-Pinnaclife-background.jpg
Patents
| Compositions and Methods for Wound Care | |||||||
| Abstract: The present disclosure relates to compositions for and methods of repairing the stratum corneum, compositions and methods for inhibiting excessive transepidermal water loss, compositions for and methods of treating skin that is distressed or wounded, as a result of a disease or other biological condition or process (as distinguished from wounds resulting from trauma), compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. | |||||||
| Country | Reference # | Type | Filed | Serial # | Issued | Patent # | Status |
|---|---|---|---|---|---|---|---|
| Canada | P10416CA00 | DCA | 11/23/2011 | 2,764,060 | 8/25/2015 | 2,764,060 | ISSUED |
| Germany | P10416DE00 | 7/24/2017 | 10792731.1 | 4/26/2017 | 602010041887.1 | ISSUED | |
| European Patent Convent | P10416EP00 | DCA | 11/23/2011 | 10792731.1 | 4/26/2017 | 2445483 | ISSUED |
| France | P10416FR00 | 7/24/2017 | 10792731.1 | 4/26/2017 | 2445483 | ISSUED | |
| United Kingdom | P10416GB00 | 7/24/2017 | 10792731.1 | 4/26/2017 | 2445483 | ISSUED | |
| Ireland | P10416IE00 | 7/24/2017 | 10792731.1 | 4/26/2017 | 2445483 | ISSUED | |
| Philippines | P10416PH00 | DCA | 3/10/2014 | 12014501044 | Pending | ||
| United States | P10416US01 | FCA | 6/25/2010 | 12/823,567 | 7/1/2014 | 8,765,794 | ISSUED |
| United States | P10416US02 | CIP | 3/15/2013 | 13/832,188 | 8/5/2014 | 8,796,315 | ISSUED |
| United States | P10416US03 | CON | 7/11/2014 | 14/328,843 | 4/28/2015 | 9,018,237 | ISSUED |
| Wipo | P10416WO00 | CEQ | 6/25/2010 | pct/us10/40008 | Nat Phase | ||
| Wipo | P10416WO02 | CEQ | 3/10/2014 | pct/us14/22490 | Nat Phase | ||
| Compositions for Anti-inflammatory Antioxidant Effects and Improved Respiratory Functions by Specific Histone Deacetylase Inhibition | |||||||
| Abstract: Compositions comprising LSF compositions and treatment regimens comprising administration of LSF containing compositions are disclosed. Compositions and/or regimens may optionally include the administration of vitamins, minerals, and antioxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, including diseases associated with inflammation and/or oxidative stress, are provided. Various methods for use of the LSF compositions for inhibition of histone deacetylases (HDACs) in various cells, tissues, and/or conditions are also provided. | |||||||
| Country | Reference # | Type | Filed | Serial # | Issued | Patent # | Status |
| Australia | P11129AU00 | 11/29/2016 | 2015287947 | 3/18/2018 | 2015287947 | ISSUED | |
| Canada | P11129CA00 | 11/29/2016 | 2,958,372 | Pending | |||
| European Patent Convent | P11129EP00 | 11/29/2016 | 15819066.0 | Pending | |||
| Philippines | P11129PH00 | 11/29/2016 | 1-2016-502403 | Pending | |||
| United States | P11129US01 | FCA | 7/8/2015 | 14/793,839 | 1/3/2017 | 9,532,970 | ISSUED |
| United States | P11129US02 | 11/21/2016 | 15/357,489 | Pending | |||
| United States | P11129US03 | 5/22/2018 | 15/986,013 | Pending | |||
| Wipo | P11129WO00 | CEQ | 7/8/2015 | pct/us15/39483 | Pending | ||
| Hydroxytyrosol and Oleuropein Compositions for Induction of DNA Damage, Cell Death, and LSD1 Inhibition | |||||||
| Abstract: Compositions comprising hydroxytyrosol-containing formulations and treatment regimens comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regimens may optionally include the administration of vitamins, minerals, and antioxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided. | |||||||
| Country | Reference # | Type | Filed | Serial # | Issued | Patent # | Status |
| Canada | P10414CA00 | DCA | 5/7/2015 | 2,892,375 | Pending | ||
| European Patent Convent | P10414EP00 | DCA | 5/7/2015 | 13858012.1 | Pending | ||
| Philippines | P10414PH00 | DCA | 5/7/2015 | 1-2015-501055 | 8/31/2018 | 1-2015-501055 | ISSUED |
| United States | P10414US02 | FCA | 11/27/2013 | 14/091,742 | 9/29/2015 | 9,144,555 | ISSUED |
| Wipo | P10414WO00 | CEQ | 11/27/2013 | pct/us13/72276 | Nat Phase | ||
| United States | P10414US03 | CON | 8/11/2015 | 14/823,028 | 5/30/2017 | 9,662,302 | ISSUED |
| United States | P10414US04 | 4/25/2017 | 15/496,866 | 3/19/2019 | 10,231,939 | ISSUED | |
| Nutritional Supplements | |||||||
| Abstract: A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 µg hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof. | |||||||
| Country | Reference # | Type | Filed | Serial # | Issued | Patent # | Status |
| Canada | P10415CA00 | DCA | 1/15/2012 | 2,769,819 | 7/21/2015 | 2,769,819 | ISSUED |
| Germany | P10415DE00 | 6/29/2018 | 10808641.4 | 5/30/2018 | 602010051005.0 | ISSUED | |
| European Patent Convent | P10415EP00 | DCA | 8/10/2010 | 10808641.4 | 5/30/2018 | 2464247 | ISSUED |
| France | P10415FR00 | 6/28/2018 | 10808641.4 | 5/30/2018 | 2464247 | ISSUED | |
| United Kingdom | P10415GB00 | 6/29/2018 | 10808641.4 | 5/30/2018 | 2464247 | ISSUED | |
| United States | P10415US01 | FCA | 8/10/2010 | 12/853,908 | 8/19/2014 | 8,809,311 | ISSUED |
| United States | P10415US02 | DIV | 7/14/2014 | 14/330,070 | 3/22/2016 | 9,289,401 | ISSUED |
| Wipo | P10415WO00 | CEQ | 8/10/2010 | pct/us10/45049 | Nat Phase | ||
| Olivamine-Induced Improvement in Endothelial Cells Viability and Function | |||||||
| Country | Reference # | Type | Filed | Serial # | Issued | Patent # | Status |
| United States | P11429US00 | NEW | 6/5/2015 | 14/731,441 | Published | ||
| Wipo | P11429WO00 | 6/3/2016 | PCT/US16/35742 | Published | |||
